COVID-19 patients exhibit reduced procoagulant platelet responses.
Frederik DenormeBhanu Kanth ManneIrina PortierAaron C PetreyElizabeth A MiddletonBenjamin T KileMatthew T RondinaRobert A CampbellPublished in: Journal of thrombosis and haemostasis : JTH (2020)
We observed that platelets isolated from COVID-19 patients had a reduced ability to become procoagulant compared to those from matched healthy donors, as evidenced by reduced mitochondrial depolarization and phosphatidylserine exposure following dual stimulation with thrombin and convulxin. To understand what impact reduced procoagulant platelet responses might have in vivo, we subjected mice with a platelet-specific deletion of cyclophilin D, which are deficient in procoagulant platelet formation, to a model of pulmonary microvascular thrombosis. Mice with platelets lacking cyclophilin D died significantly faster from pulmonary microvascular thrombosis compared to littermate wild-type controls. These results suggest dysregulated procoagulant platelet responses may contribute to thrombotic complications during SARS-CoV-2 infection.